Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

September

28

ATEC Advances Clinical Predictability with Procedural Solutions to be Featured at NASS 2022

Company will showcase lateral sophistication and information-based clinical influence CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc....

21

electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents

Four patents issued expanding claims related to delivery of nVNS and other therapies using...

12

Neurolens Raises $67 Million from MVM Partners, Falcon Vision/KKR, Marshall Wace & Existing Investors

Investment will be used to develop new products and drive adoption DALLAS, Texas, September 12,...

7

gammaCore Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder

(Non-Invasive Vagus Nerve Stimulation; nVNS) ROCKAWAY, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR),...

1

Exagen Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

29

Neurolens Top 30 Healthcare Company on Inc. 5000 2022 List

28th fastest-growing healthcare company on 2022 list Ranked #1,773 overall among America’s fastest-growing private...

9

Neurolenses Have Significant Impact on Reading Speed

New parallel arm study results have implications for productivity and learning Coppell, Texas, August 8,...

4

Exagen Inc. Reports Second Quarter 2022 Results

Records in AVISE® CTD Volume, Ordering Healthcare Providers and Adopters SAN DIEGO, Aug. 04, 2022 (GLOBE...

4

ATEC Reports Second Quarter 2022 Financial Results and Increases Full-Year Revenue Guidance

Total revenue grows 35% to $84 million, including organic revenue growth of 30% EOS...

4

electroCore Announces Record Second Quarter 2022 Financial Results

Record second quarter 2022 net sales of $2.2 million, increased 70% over second quarter 2021 and...

4

Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA

TIGER study to assess whether certain biomarkers from synovial biopsies of inflamed joint tissue...

12

electroCore Provides Select Second Quarter 2022 Financial Guidance

Record revenue will be at least $2.1 million; approximately 65% growth over second quarter 2021 June...

Recent developments

September

28

ATEC Advances Clinical Predictability with Procedural Solutions to be Featured at NASS 2022

September

21

electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents

September

12

Neurolens Raises $67 Million from MVM Partners, Falcon Vision/KKR, Marshall Wace & Existing Investors

September

7

gammaCore Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder

September

1

Exagen Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

August

29

Neurolens Top 30 Healthcare Company on Inc. 5000 2022 List

August

9

Neurolenses Have Significant Impact on Reading Speed

August

4

Exagen Inc. Reports Second Quarter 2022 Results

August

4

ATEC Reports Second Quarter 2022 Financial Results and Increases Full-Year Revenue Guidance

August

4

electroCore Announces Record Second Quarter 2022 Financial Results

August

4

Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA

July

12

electroCore Provides Select Second Quarter 2022 Financial Guidance